Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

UBT251

Stage Phase 3

Sponsor The United Bio-Technology (Hengqin) Co

Route oral and injection

Class GIP/GLP-1/glucagon

Mechanism GLP-1, GIP, and glucagon receptor triple agonist

Sources

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07648225

UBT251 Injection Phase Ⅲ Study (Overweight or Obesity). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 600. Conditions Obesity & Overweight. This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

ClinicalTrials.gov NCT07648225 protocol and results modules

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07767942

UBT251 Injection Phase Ⅲ Study (OSA-NPAP). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 150. Conditions Obstructive Sleep Apnea, Obesity. The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety. The key research question is: Does UBT251 reduce the Apnea-Hypopnea

ClinicalTrials.gov NCT07767942 protocol and results modules

registry, as of 2026-09-08Stale

https://clinicaltrials.gov/study/NCT07806851

UBT251 Injection Phase Ⅲ Study (OSA-PAP). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 150. Conditions Obstructive Sleep Apnea; Obesity. UBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure therapy.Participants will complete the following study pr

ClinicalTrials.gov NCT07806851 protocol and results modules

registry, as of 2026-04-21Stale

https://clinicaltrials.gov/study/NCT07395687

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 333. Conditions Overweight; Obesity. The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which trea

ClinicalTrials.gov NCT07395687 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07177469

UBT251 Injection Phase II Study (Overweight or Obesity). Overall status COMPLETED. Phases PHASE2. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 205. Conditions Obesity &Amp; Overweight. This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

ClinicalTrials.gov NCT07177469 protocol and results modules

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07134335

UBT251 Injection Phase II Clinical Study (CKD). Overall status RECRUITING. Phases PHASE2. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 180. Conditions Obesity &Amp; Overweight; Chronic Kidney Disease. This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population

ClinicalTrials.gov NCT07134335 protocol and results modules

registry, as of 2026-08-25Stale

https://clinicaltrials.gov/study/NCT07785934

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 48. Conditions Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics. This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity. The primary objective of Cohort 1 is to evaluate the effect of UBT251 Injection on the pha

ClinicalTrials.gov NCT07785934 protocol and results modules

registry, as of 2026-08-18Stale

https://clinicaltrials.gov/study/NCT07710768

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 44. Conditions Obesity; Overweight. The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

ClinicalTrials.gov NCT07710768 protocol and results modules

publication, as of 2026-10-23Stale

https://pubmed.ncbi.nlm.nih.gov/42843337/

agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. In this multicenter, randomized, double-blind, placebo-controlled phase 2

PMID 42843337

Studies

UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

Registry NCT07648225

Phase Phase 3

Status Active, not recruiting

Enrollment 600

Start 2026-09-04

Primary completion 2027-09-29

Study completion 2027-11-03

Catalyst Primary completion. 2027-09-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

UBT251 Injection 4.0 mg

Dose 4.0 mg

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity & Overweight

UBT251 Injection 6.0 mg

Dose 6.0 mg

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity & Overweight

UBT251 Injection Placebo 4.0 mg

Dose 4.0 mg

Regimen once weekly

Weeks 52

Population Obesity & Overweight

UBT251 Injection Placebo 6.0 mg

Dose 6.0 mg

Regimen once weekly

Weeks 52

Population Obesity & Overweight

UNISHAPE-OSA-1

Registry NCT07767942

Phase Phase 3

Status Not yet recruiting

Enrollment 150

Start 2026-12-01

UBT251 Dose 1

Regimen weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea, Obesity

UBT251 Dose 2

Regimen weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea, Obesity

Placebo

Regimen weekly

Weeks 52

Population Obstructive Sleep Apnea, Obesity

UNISHAPE-OSA-2

Registry NCT07806851

Phase Phase 3

Status Not yet recruiting

Enrollment 150

Start 2026-10-10

UBT251 Dose 1

Regimen once weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea; Obesity

UBT251 Dose 2

Regimen once weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea; Obesity

Placebo

Regimen once weekly

Weeks 52

Population Obstructive Sleep Apnea; Obesity

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Registry NCT07395687

Phase Phase 2

Status Recruiting

Enrollment 333

Start 2026-02-02

Primary completion 2027-01-14

Study completion 2027-02-18

Catalyst Primary completion. 2027-01-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A - UBT251

Comparator placebo

Population Overweight; Obesity

Part A - placebo

Population Overweight; Obesity

Part B - Arm A (UBT251)

Comparator placebo

Population Overweight; Obesity

Part B - Arm B (UBT251)

Comparator placebo

Population Overweight; Obesity

Part B - Arm C (UBT251)

Comparator placebo

Population Overweight; Obesity

Part B - Arm D (UBT251)

Comparator placebo

Population Overweight; Obesity

Part B - Arm E (UBT251)

Comparator placebo

Population Overweight; Obesity

Part B - placebo

Population Overweight; Obesity

Part C - UBT251 dose 1

Comparator placebo

Population Overweight; Obesity

Part C - UBT251 dose 2

Comparator placebo

Population Overweight; Obesity

Part C - UBT251 dose 3

Comparator placebo

Population Overweight; Obesity

UBT251 Injection Phase II Study (Overweight or Obesity)

Registry NCT07177469

Phase Phase 2

Status Completed

Enrollment 205

Start 2025-03-14

Primary completion 2025-10-22

Study completion 2025-11-19

Catalyst Primary completion. 2025-10-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

UBT251 Injection 2.0 mg

Dose 2.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight

UBT251 Injection 4.0 mg(ID 0.5 mg)

Dose 0.5 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight

UBT251 Injection 4.0 mg(ID 1.0 mg)

Dose 1.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight

UBT251 Injection 6.0 mg

Dose 6.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight

UBT251 Injection Phase II Clinical Study (CKD)

Registry NCT07134335

Phase Phase 2

Status Recruiting

Enrollment 180

Start 2025-09-01

Primary completion 2030-07-11

Study completion 2030-07-11

Catalyst Primary completion. 2030-07-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

2.0 mg group

Dose 2.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight; Chronic Kidney Disease

4.0 mg group

Dose 4.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight; Chronic Kidney Disease

6.0 mg group

Dose 6.0 mg

Regimen once weekly

Weeks 24

Population Obesity &Amp; Overweight; Chronic Kidney Disease

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

Registry NCT07785934

Phase Phase 1

Status Recruiting

Enrollment 48

Start 2026-05-27

UBT251

Regimen weekly

Weeks 251

Population Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Registry NCT07710768

Phase Phase 1

Status Recruiting

Enrollment 44

Start 2026-07-15

Primary completion 2027-04-07

Study completion 2027-04-07

Catalyst Primary completion. 2027-04-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

UBT251

Population Obesity; Overweight

Cocktail (Warfarin/Caffeine/Midazolam)

Population Obesity; Overweight